Site icon pharmaceutical daily

Mainz Biomed N.V. strengthens partnership with TestDNA to advance colorectal cancer detection in Poland

Mainz Biomed N.V., a company focused on molecular genetics diagnostics for early cancer detection, is confirming its collaboration with TestDNA at the forthcoming 10th Gdańsk Gastroenterology Symposium scheduled for January 12th–13th, 2024. The joint effort aims to progress the detection of colorectal cancer (CRC) in Poland, with a focus on introducing innovative approaches that can improve treatment choices and elevate survival rates through early identification of the disease.

The company says that the upcoming symposium, which will bring together leading experts in gastroenterology, hepatology, and gastrointestinal endoscopy from Poland, will showcase Mainz Biomed and TestDNA as exhibitors. Furthermore, both companies are set to kick off the second day of the event by hosting a panel discussion focused on diseases of the lower digestive tract. This implies active participation and involvement by Mainz Biomed and TestDNA in the symposium’s agenda, emphasizing their contribution to discussions on relevant medical topics.

With a high demand for reliable non-invasive screening methods in Poland, such as ColoAlert, due to low willingness for colonoscopies, the collaboration addresses the annual incidence of 19,000 new cases and approximately 12,000 CRC-related deaths. The estimated addressable market in Poland is around 21 million patients, emphasizing the importance of effective at-home screening tests with early-stage detection capabilities.

Exit mobile version